Next-Generation polio vaccine enters human testing
⭐️ VACCINE ⭐️
Not yet recruiting
This trial tests a new recombinant polio vaccine (rPV) against the current standard IPOL vaccine in healthy adults aged 18 to 60. The goal is to see if the new vaccine is safe and triggers a strong immune response. It is a small, early-stage study to gather initial data.
Phase: PHASE1 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 12, 2026 00:00 UTC